The intraocular pressure lowering effect in 30 patients with raised intraocular pressure and open angles following a single application in a randomised double-masked fashion of four concentrations of D-timolol (0-25%, 0 5%, 1-0%, and 2-0%), 0.25% L-timolol, and placebo are presented. The percentage reduction in intraocular pressure after four hours following single-drop instillation' range from 20% to 25% in the D-timolol group, 32% in the L-timOlOl group, and only 8% in the placebo group of treated eyes.
The role of L-timolol (that is, the S-enantiomer of timolol) in the treatment of glaucoma is well established. 1-3 The success of L-timolOl can be attributed to its relatively long duration of action, the minimal development of tolerance, and lack of membrane stabilising (local anaesthetic) activity. However, L- timolol, being a non-selective P3-adrenergic blocking agent, must be used with caution in patients with known contraindications to the systemic use of 13-adrenergic receptor blocking drugs. These include bronchial asthma, sinus bradycardia and greater than first degree heart block, and cardiogenic shock. Any systemically absorbed drug following topical administration may affect extraocular ,3-adrenergic receptor systems in the same patients.
The R-enantiomer of timolol (D-timolol) is also a non-specific P-adrenergic blocker, but its potency as a 13-blocker is substantially less than that of Ltimolol.4 D-Timolol has only 3% of the potency of Ltimolol in blocking the isoproterenol-induced synthesis of adenosine 3-3, 5 ,-blocking drugs and clonidine, or taking adrenergic augmenting psychotropic drugs such as monoamineoxidase inhibitors or tricyclic antidepressants were excluded from the study.
Thirty patients gave their informed written consent to take part in the trial (and were free to remove themselves from the trial without explanation at any time). Each of the 30 patients received two of the six possible treatments. The allocation of treatments was such that each was given to 10 different patients. Only one eye was treated, and the eye to be treated and the treatment to be received were determined by a random allocation schedule. Each treatment was delivered from identical 5 ml ocumeters containing one of the following six compounds; 0-25% Dtimolol, 0.5% D-timOlOl, 1-0% D-timOlOl, 2-0% Dtimolol, 0-25% L-timolol, and placebo to match (vehicle of D-timolOl).
All intraocular pressure reducing medications were washed out for at least two weeks. Within this period all patients had, before treatment, history taken and examination made to ensure that they satisfied admission and exclusion criteria.
Immediately prior to treatment the resting heart rate and blood pressure were measured in all 30 patients after they had been sitting for four minutes. The visual acuity, pupillary size, and results of an external ocular examination followed by an initial applanation intraocular pressure were recorded for both eyes. The first of the randomly assigned drops was instilled into the conjunctival sac of one randomly selected eye. All examinations were repeated at one, two, and four hours after treatment.
Each patient returned two weeks later to receive the second treatment in the same eye as the first treatment. No ocular treatment was allowed during the period between the first and second treatment days. Examinations for the second treatment day followed the same schedule as for the first day. Any subjective side effects following topical instillation of any of the treatments were noted.
Results
All 30 patients completed the study. The mean IOP in the treated eyes at the studied time points are shown in Fig. 1 0-5=D-timolol0-5%. 2-0=D-timolol2%. intraocular pressure had fallen by varying amounts according to the treatment used (Table 1) . Placebo and 0O25% D-timolol did not produce a significant reduction in intraocular pressure. However, 0-5, 1%, and 2% D-timolol and 0-25% L-timolol did all produce a significant reduction in intraocular pressure four hours after treatment in comparison with placebo (variance ratio 2-6; p<0-05). These reductions in intraocular pressure did not differ significantly from one another. Fig. 2 and Table 2 show the mean change in intraocular pressure in the treated eyes over time following single-drop instillation of each treatment. The initial intraocular pressures in untreated eyes were similar in each group (variance ratio 1-5%; p>0.05) ranging from 27-20 to 31 90 mmHg ( Table  3 ). The pretreatment mean intraocular pressures for each group of 10 untreated eyes were the same or slightly higher (NS) than the treated fellow eyes. The mean intraocular pressures in the untreated eyes for each treatment group were all lowered four hours after treatment (Table 3) . No significant difference could be detected in the untreated eyes between treatments or between treatment and placebo. Any 
